Efficient osteoclast differentiation requires local complement activation

Blood

Volumn 116, Issue 22, 2010, Pages 4456-4463

  Tu, Zhidan ^a,b   Bu, Hong ^b   Dennis, James E ^a   Lin, Feng ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COLONY STIMULATING FACTOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C5A; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MACROPHAGE; MALE; MOUSE; NEWBORN; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; SUPPLEMENTATION; WILD TYPE;

EID: 78649463184     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-263590     Document Type: Article

References (39)

1. Hugli TE, Muller-Eberhard HJ. Anaphylatoxins: C3a and C5a. Adv Immunol. 1978;26:1-53.
2. Vidarsson G, van de Winkel JG. Fc receptor and complement receptor-mediated phagocytosis in host defence. Curr Opin Infect Dis. 1998;11(3):271-278.
3. Fearon DT. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med. 1980;152(1):20-30.
4. Moore MD, Cooper NR, Tack BF, Nemerow GR. Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. Proc Natl Acad Sci U S A. 1987;84(24):9194-9198.
5. Fearon DT. The human C3b receptor. Springer Semin Immunopathol. 1983;6(2-3):159-172.
6. Myones BL, Dalzell JG, Hogg N, Ross GD. Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR4) activity resembling CR3. J Clin Invest. 1988;82(2):640-651.
7. Ames RS, Li Y, Sarau HM, et al. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem. 1996;271(34):20231-20234.
8. Boulay F, Mery L, Tardif M, Brouchon L, Vignais P. Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells. Biochemistry. 1991;30(12):2993-2999.
9. Ember JA, Hugli TE. Complement factors and their receptors. Immunopharmacology. 1997;38(1-2):3-15.
10. Hugli TE. Structure and function of the anaphylatoxins. Springer Semin Immunopathol. 1984;7(2-3):193-219.
11. Haas PJ, van Strijp J. Anaphylatoxins: their role in bacterial infection and inflammation. Immunol Res. 2007;37(3):161-175.
12. Sato T, Abe E, Jin CH, et al. The biological roles of the third component of complement in osteoclast formation. Endocrinology. 1993;133(1):397-404.
13. Wessels MR, Butko P, Ma M, Warren HB, Lage AL, Carroll MC. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci U S A. 1995;92(25):11490-11494.
14. Xu Y, Ma M, Ippolito GC, Schroeder HW Jr, Carroll MC, Volanakis JE. Complement activation in factor D - deficient mice. Proc Natl Acad Sci U S A. 2001;98(25):14577-14582.
15. Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol. 2003;170(3):1517-1523.
16. Humbles AA, Lu B, Nilsson CA, et al. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature. 2000;406(6799):998-1001.
17. Hopken UE, Lu B, Gerard NP, Gerard C. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature. 1996;383(6595):86-89.
18. Udagawa N, Takahashi N, Jimi E, et al. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NFkappaB ligand. Bone. 1999;25(5):517-523.
19. Sato T, Hong MH, Jin CH, et al. The specific production of the third component of complement by osteoblastic cells treated with 1 alpha,25-dihydroxyvitamin D3. FEBS Lett. 1991;285(1):21-24.
20. Takahashi N, Udagawa N, Akatsu T, Tanaka H, Isogai Y, Suda T. Deficiency of osteoclasts in osteopetrotic mice is due to a defect in the local microenvironment provided by osteoblastic cells. Endocrinology. 1991;128(4):1792-1796.
21. Tanaka S, Takahashi N, Udagawa N, et al. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest. 1993;91(1):257-263. (Pubitemid 23037280)
22. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390(6656):175-179.
23. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95(7):3597-3602.
24. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309-319.
25. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998;139(3):1329-1337.
26. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology. 1998;139(11):4743-4746.
27. Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman GD. IL-6 stimulates osteoclast-like multinucleated cell formation in long-term human marrow cultures by inducing IL-1 release. J Immunol. 1990;144(11):4226-4230. (Pubitemid 20187761)
28. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992;257(5066):88-91.
29. Heeger PS, Lalli PN, Lin F, et al. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med. 2005;201(10):1523-1530.
30. Sacks SH, Zhou W. Allograft rejection: effect of local synthesis of complement. Springer Semin Immunopathol. 2005;27(3):332-344.
31. Quinn JM, Whitty GA, Byrne RJ, Gillespie MT, Hamilton JA. The generation of highly enriched osteoclast-lineage cell populations. Bone. 2002;30(1):164-170.
32. Choi HG, Kim JM, Kim BJ, Yoo YJ, Cha JH. Mouse strain-dependent osteoclastogenesis in response to lipopolysaccharide. J Microbiol. 2007;45(6):566-571.
33. Schiller C, Gruber R, Ho GM, et al. Interaction of triiodothyronine with 1alpha,25-dihydroxyvitamin D3 on interleukin-6-dependent osteoclast-like cell formation in mouse bone marrow cell cultures. Bone. 1998;22(4):341-346.
34. Gao Y, Morita I, Maruo N, Kubota T, Murota S, Aso T. Expression of IL-6 receptor and GP130 in mouse bone marrow cells during osteoclast differentiation. Bone. 1998;22(5):487-493.
35. Katschke KJ Jr, Helmy KY, Steffek M, et al. A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. J Exp Med. 2007;204(6):1319-1325.
36. Song H, Qiao F, Atkinson C, Holers VM, Tomlinson S. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol. 2007;179(11):7860-7867.
37. Banda NK, Thurman JM, Kraus D, et al. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J Immunol. 2006;177(3):1904-1912.
38. Hietala MA, Nandakumar KS, Persson L, Fahlen S, Holmdahl R, Pekna M. Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis. Eur J Immunol. 2004;34(4):1208-1216.
39. Hietala MA, Jonsson IM, Tarkowski A, Kleinau S, Pekna M. Complement deficiency ameliorates collagen-induced arthritis in mice. J Immunol. 2002;169(1):454-459.